XML 41 R29.htm IDEA: XBRL DOCUMENT
v3.20.2

Revenue Recognition - Disaggregated Sales Analysis (Details) - USD ($) $ in Millions | 3 Months Ended | 9 Months Ended
--- | --- | ---
Sep. 30, 2020 | Sep. 30, 2019 | Sep. 30, 2020 | Sep. 30, 2019
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | $ 3,737 | $ 3,587 | $ 10,089 | $ 10,753
United States |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 2,748 | 2,644 | 7,357 | 7,918
International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 989 | 943 | 2,732 | 2,835
Orthopaedics |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 1,317 | 1,262 | 3,433 | 3,785
Orthopaedics | United States |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 937 | 872 | 2,412 | 2,596
Orthopaedics | International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 380 | 390 | 1,021 | 1,189
Orthopaedics | Knees |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 435 | 426 | 1,108 | 1,305
Orthopaedics | Knees | United States |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 332 | 318 | 833 | 962
Orthopaedics | Knees | International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 103 | 108 | 275 | 343
Orthopaedics | Hips |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 334 | 332 | 866 | 1,011
Orthopaedics | Hips | United States |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 223 | 211 | 564 | 643
Orthopaedics | Hips | International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 111 | 121 | 302 | 368
Orthopaedics | Trauma and Extremities |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 430 | 407 | 1,152 | 1,197
Orthopaedics | Trauma and Extremities | United States |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 285 | 262 | 753 | 768
Orthopaedics | Trauma and Extremities | International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 145 | 145 | 399 | 429
Orthopaedics | Other |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 118 | 97 | 307 | 272
Orthopaedics | Other | United States |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 97 | 81 | 262 | 223
Orthopaedics | Other | International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 21 | 16 | 45 | 49
MedSurg |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 1,600 | 1,552 | 4,546 | 4,680
MedSurg | United States |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 1,269 | 1,247 | 3,567 | 3,755
MedSurg | International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 331 | 305 | 979 | 925
MedSurg | Instruments |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 467 | 452 | 1,308 | 1,417
MedSurg | Instruments | United States |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 369 | 357 | 1,028 | 1,121
MedSurg | Instruments | International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 98 | 95 | 280 | 296
MedSurg | Endoscopy |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 467 | 474 | 1,238 | 1,424
MedSurg | Endoscopy | United States |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 380 | 377 | 997 | 1,136
MedSurg | Endoscopy | International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 87 | 97 | 241 | 288
MedSurg | Medical |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 600 | 554 | 1,819 | 1,627
MedSurg | Medical | United States |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 455 | 442 | 1,363 | 1,288
MedSurg | Medical | International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 145 | 112 | 456 | 339
MedSurg | Sustainability |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 66 | 72 | 181 | 212
MedSurg | Sustainability | United States |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 65 | 71 | 179 | 210
MedSurg | Sustainability | International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 1 | 1 | 2 | 2
Neurotechnology and Spine |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 820 | 773 | 2,110 | 2,288
Neurotechnology and Spine | United States |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 542 | 525 | 1,378 | 1,567
Neurotechnology and Spine | International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 278 | 248 | 732 | 721
Neurotechnology and Spine | Neurotechnology |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 518 | 490 | 1,370 | 1,443
Neurotechnology and Spine | Neurotechnology | United States |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 323 | 316 | 835 | 929
Neurotechnology and Spine | Neurotechnology | International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 195 | 174 | 535 | 514
Neurotechnology and Spine | Spine |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 302 | 283 | 740 | 845
Neurotechnology and Spine | Spine | United States |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 219 | 209 | 543 | 638
Neurotechnology and Spine | Spine | International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | $ 83 | $ 74 | $ 197 | $ 207

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_DisaggregationOfRevenueLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 28 -Subparagraph (f) -URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 235 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -URI http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227 + Details
Name: | us-gaap_Revenues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=us-gaap_NonUsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=syk_OrthopaedicsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=syk_KneesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=syk_HipsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=syk_TraumaandExtremitiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=syk_OtherOrthopaedicsDomain
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=syk_MedsurgMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=syk_InstrumentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=syk_EndoscopyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=syk_MedicalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=syk_SustainabilityMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=syk_NeurotechnologyAndSpineMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=syk_NeurotechnologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=syk_SpineMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |